Literature DB >> 23703888

Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994.

Mariana Lazo1, Ruben Hernaez, Mark S Eberhardt, Susanne Bonekamp, Ihab Kamel, Eliseo Guallar, Ayman Koteish, Frederick L Brancati, Jeanne M Clark.   

Abstract

Previous estimates of the prevalence of nonalcoholic fatty liver disease (NAFLD) in the US population relied on measures of liver enzymes, potentially underestimating the burden of this disease. We used ultrasonography data from 12,454 adults who participated in the Third National Health and Nutrition Examination Survey, conducted in the United States from 1988 to 1994. We defined NAFLD as the presence of hepatic steatosis on ultrasonography in the absence of elevated alcohol consumption. In the US population, the rates of prevalence of hepatic steatosis and NAFLD were 21.4% and 19.0%, respectively, corresponding to estimates of 32.5 (95% confidence interval: 29.9, 35.0) million adults with hepatic steatosis and 28.8 (95% confidence interval: 26.6, 31.2) million adults with NAFLD nationwide. After adjustment for age, income, education, body mass index (weight (kg)/height (m)²), and diabetes status, NAFLD was more common in Mexican Americans (24.1%) compared with non-Hispanic whites (17.8%) and non-Hispanic blacks (13.5%) (P = 0.001) and in men (20.2%) compared with women (15.8%) (P < 0.001). Hepatic steatosis and NAFLD were also independently associated with diabetes, with insulin resistance among people without diabetes, with dyslipidemia, and with obesity. Our results extend previous national estimates of the prevalence of NAFLD in the US population and highlight the burden of this disease. Men, Mexican Americans, and people with diabetes and obesity are the most affected groups.

Entities:  

Keywords:  ethnic variation; nonalcoholic fatty liver disease; population surveys; prevalence

Mesh:

Year:  2013        PMID: 23703888      PMCID: PMC3698993          DOI: 10.1093/aje/kws448

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  37 in total

1.  Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group.

Authors:  S Bellentani; G Saccoccio; G Costa; C Tiribelli; F Manenti; M Sodde; L Saveria Crocè; F Sasso; G Pozzato; G Cristianini; G Brandi
Journal:  Gut       Date:  1997-12       Impact factor: 23.059

2.  Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III).

Authors:  Suthat Liangpunsakul; Naga Chalasani
Journal:  Am J Med Sci       Date:  2005-03       Impact factor: 2.378

3.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

Authors:  C A Matteoni; Z M Younossi; T Gramlich; N Boparai; Y C Liu; A J McCullough
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

4.  Prevalence of overweight and obesity in the United States, 1999-2004.

Authors:  Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal
Journal:  JAMA       Date:  2006-04-05       Impact factor: 56.272

5.  Association between inflammation and insulin resistance in U.S. nondiabetic adults: results from the Third National Health and Nutrition Examination Survey.

Authors:  Jing Chen; Rachel P Wildman; L Lee Hamm; Paul Muntner; Kristi Reynolds; Paul K Whelton; Jiang He
Journal:  Diabetes Care       Date:  2004-12       Impact factor: 19.112

6.  Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.

Authors:  Jeffrey D Browning; Lidia S Szczepaniak; Robert Dobbins; Pamela Nuremberg; Jay D Horton; Jonathan C Cohen; Scott M Grundy; Helen H Hobbs
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

7.  The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002.

Authors:  George N Ioannou; Edward J Boyko; Sum P Lee
Journal:  Am J Gastroenterol       Date:  2006-01       Impact factor: 10.864

8.  Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991.

Authors:  R J Kuczmarski; K M Flegal; S M Campbell; C L Johnson
Journal:  JAMA       Date:  1994-07-20       Impact factor: 56.272

9.  Risk of fatty infiltration or cirrhosis of the liver in relation to ethanol consumption: a case-control study.

Authors:  R A Coates; M L Halliday; J G Rankin; S V Feinman; M M Fisher
Journal:  Clin Invest Med       Date:  1986       Impact factor: 0.825

10.  Brief communication: clinical implications of short-term variability in liver function test results.

Authors:  Mariana Lazo; Elizabeth Selvin; Jeanne M Clark
Journal:  Ann Intern Med       Date:  2008-03-04       Impact factor: 25.391

View more
  305 in total

Review 1.  Epidemiology of NAFLD and Type 2 Diabetes: Health Disparities Among Persons of Hispanic Origin.

Authors:  Mariana Lazo; Usama Bilal; Rafael Perez-Escamilla
Journal:  Curr Diab Rep       Date:  2015-12       Impact factor: 4.810

2.  Serum 25-hydroxyvitamin-D and nonalcoholic fatty liver disease: Does race/ethnicity matter? Findings from the MESA cohort.

Authors:  Samar R El Khoudary; Saad Samargandy; Irfan Zeb; Temitope Foster; Ian H de Boer; Dong Li; Matthew J Budoff
Journal:  Nutr Metab Cardiovasc Dis       Date:  2019-09-10       Impact factor: 4.222

Review 3.  Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis.

Authors:  Siddharth Singh; Sudhakar K Venkatesh; Rohit Loomba; Zhen Wang; Claude Sirlin; Jun Chen; Meng Yin; Frank H Miller; Russell N Low; Tarek Hassanein; Edmund M Godfrey; Patrick Asbach; Mohammad Hassan Murad; David J Lomas; Jayant A Talwalkar; Richard L Ehman
Journal:  Eur Radiol       Date:  2015-08-28       Impact factor: 5.315

4.  Longer lactation duration is associated with decreased prevalence of non-alcoholic fatty liver disease in women.

Authors:  Veeral H Ajmera; Norah A Terrault; Lisa B VanWagner; Monika Sarkar; Cora E Lewis; John J Carr; Erica P Gunderson
Journal:  J Hepatol       Date:  2018-11-01       Impact factor: 25.083

5.  Accurate Identification of Fatty Liver Disease in Data Warehouse Utilizing Natural Language Processing.

Authors:  Joseph S Redman; Yamini Natarajan; Jason K Hou; Jingqi Wang; Muzammil Hanif; Hua Feng; Jennifer R Kramer; Roxanne Desiderio; Hua Xu; Hashem B El-Serag; Fasiha Kanwal
Journal:  Dig Dis Sci       Date:  2017-08-31       Impact factor: 3.199

6.  Determination of Fatty Acid Oxidation and Lipogenesis in Mouse Primary Hepatocytes.

Authors:  Thomas E Akie; Marcus P Cooper
Journal:  J Vis Exp       Date:  2015-08-27       Impact factor: 1.355

7.  Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults.

Authors:  Yvonne N Flores; Rafael Velázquez-Cruz; Paula Ramírez; Manuel Bañuelos; Zuo-Feng Zhang; Hal F Yee; Shen-Chih Chang; Samuel Canizales-Quinteros; Manuel Quiterio; Guillermo Cabrera-Alvarez; Nelly Patiño; Jorge Salmerón
Journal:  Mol Biol Rep       Date:  2016-10-17       Impact factor: 2.316

8.  Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI.

Authors:  Scott M Thompson; Ishan Garg; Eric C Ehman; Shannon P Sheedy; Candice A Bookwalter; Rickey E Carter; Lewis R Roberts; Sudhakar K Venkatesh
Journal:  Br J Radiol       Date:  2018-08-29       Impact factor: 3.039

9.  Higher Glucose and Insulin Levels Are Associated with Risk of Liver Cancer and Chronic Liver Disease Mortality among Men without a History of Diabetes.

Authors:  Erikka Loftfield; Neal D Freedman; Gabriel Y Lai; Stephanie J Weinstein; Katherine A McGlynn; Philip R Taylor; Satu Männistö; Demetrius Albanes; Rachael Z Stolzenberg-Solomon
Journal:  Cancer Prev Res (Phila)       Date:  2016-08-29

10.  New Medications in the Treatment of Nonalcoholic Steatohepatitis.

Authors:  Scot Walker
Journal:  Hosp Pharm       Date:  2018-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.